Navigation Links
Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
Date:11/8/2013

2-mer non-coding RNA that negatively regulates gene/networks and has been reported to be up-regulated in fibrotic kidney diseases in both animal models and human patients (Chau, B. N. et al. Sci Transl Med. 2012; Zhong X, et al. (2013) Diabetologia (2013).  Previous reports have demonstrated that treatment with an anti-miR-21 significantly attenuates chronic kidney disease progression in a collagen 4A3 deficient mouse model.  Regulus' miR-21 therapeutic development program, which is partnered with Sanofi, is currently in preclinical testing for both kidney fibrosis and hepatocellular carcinoma.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company.   Regulus has a well-balanced microRNA therapeutic pipeline entering clinical development, an emerging microRNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases.  Regulus is also developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122, for the treatment of chronic hepatitis C virus infection.  Regulus' commitment to innovation and its leadership in the microRNA field have enabled the formation of strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi.  In addition, Regulus has formed a research collaboration with Biogen Idec around its emerging m
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
2. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
3. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
4. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
5. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
6. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
7. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
8. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
9. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
10. Regulus to Present at Future Leaders in the Biotech Industry Conference
11. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- CVS Caremark Corporation (NYSE: CVS ) will ... 2014, at 8:30 a.m. (EDT) with analysts and investors ... An audio webcast of the conference call will ... the CVS Caremark website for all interested parties.  To ... will be archived and available on the web site ...
(Date:7/25/2014)... July 25, 2014  Acsis Inc., the market ... serialization solutions, has recently posted an article, ... current and future needs for companies, extended supply ... supply chain model no longer work today.  The ... the growth of mobile technology, machine to machine ...
(Date:7/25/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... Diagnostic Device An ophthalmic diagnostic device ... or deficiency in the human visual pathway. Ophthalmic devices ... presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and dry eyes. ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... 2011 Thoratec Corporation (Nasdaq: THOR ), a ... support and restore failing hearts, today announced that it will ... 2011 on Tuesday, November 1. The company will ... operating activities, open to all interested parties, at 1:30 p.m., ...
... 2011 NxStage Medical, Inc. (Nasdaq: ... products, today announced it ranked 141 on Deloitte,s Technology ... media, telecommunications, life sciences and clean technology companies in ... year revenue growth during the period from 2006–2010. NxStage ...
Cached Medicine Technology:Thoratec Schedules Third Quarter Conference Call, Webcast 2NxStage® Ranked Number 141 on the Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 2NxStage® Ranked Number 141 on the Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 3
(Date:7/25/2014)... Unlike children, the vast majority of adults finish all of ... to a new study. This is true for ... researchers from Cornell University revealed. They noted their findings ... eating habits make better choices. "If you put it ... Wansink, director of the Cornell Food and Brand Lab, ...
(Date:7/25/2014)... genes are switched on or off plays a key ... metabolism, UT Southwestern Medical Center researchers have found., The ... obesity and diabetes, since the transcription factor involved ... influence the body,s sensitivity to insulin and leptin signaling. ... regulation of food intake and sugar disposal, and obesity ...
(Date:7/25/2014)... July 25, 2014 The American Brain ... volunteer network “ABTA CommYOUnity™” during its annual patient and ... time for the brain tumor community as we – ... and caregiver support services and funding brain tumor research ... passionate about brain tumor awareness and getting our materials ...
(Date:7/25/2014)... Progress in understanding the molecular genetics of ... promising brain tumor treatments, according to Patrick Wen, MD, ... Center for Neuro-Oncology, Dana-Farber Cancer Institute. , At the ... Conference in Chicago, July 25-26, Dr. Wen will moderate ... impacting the development of new treatments and advancing strategies ...
(Date:7/25/2014)... San Jose, CA (PRWEB) July 25, 2014 ... MaaS360 WorkPlace Partner Program . Splashtop Business and ... MaaS360 Market, and will leverage the MaaS360 WorkPlace ... corporate data. , Splashtop Business and Splashtop Enterprise offer ... using any device. High performance, ease of ...
Breaking Medicine News(10 mins):Health News:Most Adults Are Members of 'Clean Plate Club' 2Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 2Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 3Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 4
... is very rare, affecting approximately one in every 100,000 ... i.e. they are born with empty eye sockets. This ... in the normal way in the first 28 days ... fitted with prosthetic eyes to allow normal facial// development. ...
... which occurs when the heart becomes so enlarged that it ... affects 35 in every 100,000 people. Researchers in the United ... journal Science that a defect in the gene phospholamban may ... the flow of calcium through the heart, enabling it to ...
... using a new imaging technique based on Magnetic Resonance ... now, MRI was used to show how Alzheimer's disease ... for memory and learning. And post-mortem studies revealed how ... the first time a three-dimensional time lapse video of ...
... by scientists at the Johns Hopkins School of Public Health ... have called for urgent research into the impact of soya ... chemical in soya can damage the male reproductive organs. Though ... effect on humans, its effects on rats were so severe ...
... published in the February issue of the British Medical Journal ... more at risk of heart disease later in life than ... live infant in Scotland during the years 1981-85, were identified ... miscarriage or repeated miscarriages. Then, during 1981 to 1999, the ...
... blood has been believed to be the most ... heart disease is associated with increased levels of ... LDL(Low-Density Lipoprotein)or 'bad' cholesterol and HDL(High-Density Lipoprotein) or ... researchers in Canada and Sweden are now putting ...
Cached Medicine News:Health News:Miscarriage during pregnancy and heart disease linked 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: